Richard Nolan Townsend Sells 25,947 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 25,947 shares of Lexeo Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total value of $116,242.56. Following the completion of the transaction, the chief executive officer owned 377,817 shares of the company’s stock, valued at approximately $1,692,620.16. This trade represents a 6.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Richard Nolan Townsend also recently made the following trade(s):

• On Monday, May 18th, Richard Nolan Townsend sold 3,342 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $5.06, for a total value of $16,910.52.
• On Monday, April 6th, Richard Nolan Townsend sold 55,000 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $5.69, for a total transaction of $312,950.00.

Lexeo Therapeutics Trading Up 5.4%

Lexeo Therapeutics stock opened at $4.69 on Friday. Lexeo Therapeutics, Inc. has a 12-month low of $3.60 and a 12-month high of $10.99. The firm has a 50-day moving average price of $5.09 and a 200-day moving average price of $6.60. The firm has a market capitalization of $368.26 million, a PE ratio of -3.23 and a beta of 1.42.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. As a group, sell-side analysts predict that Lexeo Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on LXEO shares. Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings downgraded Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 25th. Chardan Capital reissued a “buy” rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a research report on Monday, May 11th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.75.

Institutional Trading of Lexeo Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of LXEO. Allworth Financial LP increased its holdings in shares of Lexeo Therapeutics by 1,002.9% in the 4th quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock valued at $34,000 after acquiring an additional 3,079 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Lexeo Therapeutics by 69.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock worth $35,000 after purchasing an additional 1,459 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Lexeo Therapeutics in the 4th quarter valued at about $37,000. California State Teachers Retirement System boosted its stake in Lexeo Therapeutics by 123.7% in the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after acquiring an additional 2,148 shares in the last quarter. Finally, Cerity Partners LLC acquired a new stake in shares of Lexeo Therapeutics in the 2nd quarter worth $50,000. Institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.